Edition:
United States

Edwards Lifesciences Corp (EW.N)

EW.N on New York Stock Exchange

94.30USD
4:02pm EDT
Change (% chg)

$0.83 (+0.89%)
Prev Close
$93.47
Open
$93.47
Day's High
$95.32
Day's Low
$93.30
Volume
621,003
Avg. Vol
565,982
52-wk High
$121.75
52-wk Low
$81.13

EW.N

Chart for EW.N

About

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient's diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan... (more)

Overall

Beta: 0.62
Market Cap(Mil.): $19,861.98
Shares Outstanding(Mil.): 212.50
Dividend: --
Yield (%): --

Financials

  EW.N Industry Sector
P/E (TTM): 35.75 46.84 29.63
EPS (TTM): 2.61 -- --
ROI: 15.07 6.91 13.01
ROE: 22.24 10.89 14.16

BRIEF-German patent court issues initial decision

* District court in Germany ruled that Boston Scientific's lotus valve infringes one of co's patents for transcatheter aortic valves

Mar 09 2017

BRIEF-Boston Scientific receives favorable rulings in Edwards Lifesciences litigation

* Boston scientific receives favorable rulings in edwards lifesciences litigation

Mar 09 2017

Edwards Lifesciences fourth-quarter sales, profit top expectations

Edwards Lifesciences Corp on Wednesday reported higher-than-expected fourth-quarter profit and revenue on surging demand for its minimally invasive heart valve replacement systems.

Feb 01 2017

Edwards Lifesciences 4th-quarter sales, profit top expectations

Feb 1 Edwards Lifesciences Corp on Wednesday reported higher-than-expected fourth-quarter profit and revenue on surging demand for its minimally invasive heart valve replacement systems.

Feb 01 2017

BRIEF-Edwards Lifesciences Corp Q4 EPS $0.73

* Q4 global transcatheter heart valve therapy sales up 29 percent to $432 million

Feb 01 2017

Edwards wins more than $20 million in interest in heart valve dispute

A federal judge in Boston awarded Edwards Lifesciences Corp $20.7 million in prejudgment interest on top of the $91 million it already won in a trade secret lawsuit against rival Neovasc Inc, bringing the total to more than $111 million.

Jan 19 2017

Edwards Lifesciences to buy Israel's Valtech for up to $690 million

JERUSALEM Edwards Lifesciences Corp on Monday said it has agreed to buy Israel's Valtech Cardio for $340 million in stock and cash, with the potential for an additional $350 million in pre-specified milestone-driven payments over the next 10 years.

Nov 28 2016

UPDATE 1-Edwards Lifesciences to buy Israel's Valtech for up to $690 mln

JERUSALEM, Nov 28 Edwards Lifesciences Corp on Monday said it has agreed to buy Israel's Valtech Cardio for $340 million in stock and cash, with the potential for an additional $350 million in pre-specified milestone-driven payments over the next 10 years.

Nov 28 2016

Edwards Lifesciences to buy Israel's Valtech for up to $690 mln

JERUSALEM, Nov 28 Edwards Lifesciences Corp on Monday said it has agreed to buy Israel's Valtech Cardio for $340 million in stock and cash, with the potential for an additional $350 million in pre-specified milestone-driven payments over the next 10 years.

Nov 28 2016

BRIEF-Edwards enters into agreement to acquire Valtech Cardio

* Purchase price of Valtech is $340 million in stock and cash at closing,

Nov 28 2016

More From Around the Web

Earnings vs. Estimates